Pipeline
Pipeline

CNS + BtoS Dual-Track Strategy

CNS + BtoS Dual-Track Strategy

Novorex advances CNS and inflammation programs while leveraging its Biologics-to-Small Molecule (BtoS) strategy to transform biologically validated targets into small-molecule drug candidates, supported by real-binder validation, target engagement evidence, and partnership-ready development plans.

Novorex advances CNS and inflammation programs while leveraging its Biologics-to-Small Molecule (BtoS) strategy to transform biologically validated targets into small-molecule drug candidates, supported by real-binder validation, target engagement evidence, and partnership-ready development plans.

Pipeline Overview
Pipeline Evidence at a Glance

Programs are organized by therapeutic area, indication, development stage, and product rights. The layout keeps the familiar pipeline-table structure, but presents it as a cleaner website-native matrix.

Hit DiscoveryLead OptimizationPreclinicalPhase I
Therapeutic Area
Small Molecule
Indication
Development Progress
Product Rights
Neurodegenerative
NRX-NGT002 PDPreclinical
Parkinson's Disease
Hit DiscoveryLead OptimizationPreclinicalPhase I
In vivo Efficacy Study & Toxicology Study
Novorex
Neurodegenerative
NRX-NGT002 ADPreclinical
Alzheimer's Disease
Hit DiscoveryLead OptimizationPreclinicalPhase I
In vivo Efficacy Study & Toxicology Study
Novorex
Neurodegenerative
NRX-NGT019Lead Optimization
Parkinson's Disease (TPD)
Hit DiscoveryLead OptimizationPreclinicalPhase I
Hit to Lead
Novorex
Autoimmune
NRX-NGT009Lead Optimization
Psoriasis
Hit DiscoveryLead OptimizationPreclinicalPhase I
Hit to Lead
Novorex
Autoimmune
NRX-NGT011Hit Discovery
Undisclosed
Hit DiscoveryLead OptimizationPreclinicalPhase I
Hit
Novorex
Autoimmune
NRX-NGT012Hit Discovery
Undisclosed
Hit DiscoveryLead OptimizationPreclinicalPhase I
Hit
Novorex
Neurodegenerative
NRX-NGT018Hit Discovery
Undisclosed
Hit DiscoveryLead OptimizationPreclinicalPhase I
Hit
Novorex
Flagship program Active development program Early hit-stage program